Floatz logo

Dasatinib

Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 cohort.

Asset / SponsorPhaseRating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Fluconazole
Children's Oncology Group
Phase 3BB

View all 34 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
chronic myeloid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →